Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk

Bone Marrow Transplantation

Volumn 19, Issue 1, 1997, Pages 9-13

  Miflin, G ^a   Russell, N H ^a   Hutchinson, R M ^b   Morgan, G ^c   Potter, M ^d   Pagliuca, A ^e   Marsh, J ^f   Bell, A ^g   Milligan, D ^h   Lumley, M ^h   Cook, G ⁱ   Franklin, I ⁱ  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ST GEORGE S HOSPITAL   (United Kingdom)

^g POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Allogeneic transplantation; CD34+ cells; G CSF; Peripheral blood stem cell

Indexed keywords

CD34 ANTIGEN; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; CELL COUNT; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LEUKEMIA; MALE; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TIME;

EID: 17344385687     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700603     Document Type: Article

References (15)

1. Gratwohl A, Hermans J, Baldomero H. Haemopoietic precursor cell transplants in Europe - activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 137-148.
2. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339: 640-644.
3. Russell NH, Hunter A, Rogers S et al. Peripheral-blood stem-cells as an alternative to marrow for allogeneic transplantation. Lancet 1993; 341: 1482.
4. Dreger P, Suttorp M, Haferlach T et al. Allogeneic granulocyte colony-stimulating factor mobilised peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81: 1404-1407.
5. Bensinger WI, Weaver C, Appelbaum F et al. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
6. Korbling M, Przepiorka D, Huh Y et al. Allogeneic blood stem cell transplantation for refractory leukaemia and lymphoma: potential advantages of blood over marrow allograft. Blood 1995; 85: 1659-1665.
7. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral-blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
8. Russell JA, Kuider J, Weaver M et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15: 111-115.
9. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
10. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus host disease. Blood 1995; 86: 2842-2848.
11. Haynes A, Hunter A, McQuaker G et al. Engraftment characteristics of peripheral-blood stem-cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
12. Bender J, To LB, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Haematother 1992; 1: 329-342.
13. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained haemopoietic reconstitution by peripheral blood stem cell infusion alone following high dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
14. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft versus host disease in patients given HLA-identical marrow grafts for leukaemia: long term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
15. Ringden O, Horowitz MM, Sendel P et al. Methotrexate, cyclosporine, or both to prevent graft versus host disease after HLA-identical sibling bone marrow transplants for early leukaemia? Blood 1993; 81: 1094-1101.